1646-32-8

Usage

Uses

Used in Research and Development:
1-(5-CHLOROBENZO[B]FURAN-2-YL)ETHAN-1-ONE is used as a research compound for its complex structure, which is of interest in the fields of science and pharmaceuticals. Its potential applications in these areas are being explored to understand its properties and possible uses.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(5-CHLOROBENZO[B]FURAN-2-YL)ETHAN-1-ONE is used as a starting material or intermediate in the synthesis of various pharmaceutical compounds. Its unique structure may contribute to the development of new drugs or drug candidates with potential therapeutic applications.
Used in Chemical Synthesis:
1-(5-CHLOROBENZO[B]FURAN-2-YL)ETHAN-1-ONE is used as a chemical intermediate in the synthesis of other complex organic compounds. Its reactivity and structural features make it a valuable component in the preparation of specialty chemicals and materials.

InChI:InChI=1/C10H7ClO2/c1-6(12)10-5-7-4-8(11)2-3-9(7)13-10/h2-5H,1H3

Upstream product

• 78-95-5 chloroacetone 
• 635-93-8 5-chlorosalicyclaldehyde 
• 598-31-2 1-bromoacetone 
• 1761-61-1 5-bromosalicyclaldehyde 
• 67-64-1 acetone 
• 638-07-3 ethyl (2-chloroaceto)acetate 

Downstream Products

• 58583-63-4 1-(5-chloro-2-benzofuranyl)-3-(3,5-xylyl)-2-propen-1-one 
• 62763-16-0 1-(5-methyl-2-benzofuranyl)-3-(3,5-xylyl)-2-propen-1-one 
• 7039-74-9 2-bromoacetyl-5-chlorobenzofuran 
• 1117816-34-8 ethyl 2-[1,2-diaza-3-(5-chlorobenzo[d]furan-2-yl)but-2-enylidine]-3-phenyl-1,3,4-thiadiazolin-5-carboxylate 
• 39178-59-1 5-chloro-2-ethylbenzofuran 

Relevant academic research and scientific papers

Synthesis and Anti-Cholinesterase Activity of Novel Glycosyl Benzofuranylthiazole Derivatives

Abstract: A new series of glycosyl benzofuranylthiazole derivatives were designed, synthesized, characterized, and evaluated as potential candidates to treat Alzheimer’s disease. The compounds have been synthesized by the cyclocondensation of glycosyl thiourea with a variety of 2-(bromoacetyl)benzofurans. The reaction conditions have been optimized, and good yields (79–95%) have been obtained. The synthesized compounds showed different degrees of cholinesterase inhibitory activity.

Synthesis and bioactivity of novel C2-glycosyl benzofuranylthiazoles derivatives as acetylcholinesterase inhibitors

A new series of C2-glycosyl benzofuranylthiazole derivatives was synthesised by the further cyclization of glycosyl thiourea and 2-(bromoacetyl)-benzofuran via Hantzsch’s method. The corresponding 2-(bromoacetyl)-benzofuran derivatives were obtained by the reaction from various salicylaldehydes, and the glycosyl thiourea was prepared through a series of steps from D-Glucosamine. The acetylcholinesterase-inhibitory activities of the products were tested by Ellman’s method. The most active compounds were subsequently evaluated for the 50% inhibitory concentration values. N-(1,3,4,6-tetra-O-benzyl-2-deoxy-β-D-glucopyranosyl)-4-(5-methoxy-benzofuran-2-yl)-1,3-thiazole-2-amine possessed the best acetylcholinesterase-inhibition activity with a 50% inhibitory concentration of 2.03 ± 0.26 μM.

TBAI/TBHP mediated oxidative cross coupling of ketones with phenols and carboxylic acids: Direct access to benzofurans

TBAI/TBHP mediated oxidative cross coupling of phenols and carboxylic acids with ketones has been reported under metal-free, base free, solvent free conditions enabling environmentally benign synthesis of aryloxyketones, acyloxy ketones and benzofurans. Phenoxyketones and acyloxylcarbonyl compounds were synthesized in good to high yields, where as benzofurans were synthesized in moderate yields. This method is operationally simple, works under mild conditions, using commercially available as well as inexpensive TBAI and an oxidant TBHP.

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.

One-pot synthesis of novel symmetric 1,5-di(benzofuran-2-yl)-3-(4- substituted-aryl)-pentane-1,5-dione derivatives

Salicylaldehyde and its substituted derivatives on reaction with bromoacetone under basic condition in ethanol afford corresponding benzofuran derivatives 1a-d. The compounds 1a-d on treatment with different para substituted aromatic aldehydes in presence of base and minimum amount of acetonitrile upon grinding at room temperature gives corresponding α,β-unsaturated carbonyl compounds by crossed aldol condensation, which further undergo Michael addition with 2-acetyl benzofuran to give a new class of symmetric 1,5-di(benzofuran-2-yl)-3-(4-substituted-aryl)-pentane-1,5- dione derivatives 2a-p in one step. The structures of all the newly synthesized compounds have been established by spectral studies.

Quinoxalines. Part 13: Synthesis and mass spectrometric study of aryloxymethylquinoxalines and benzo[b]furylquinoxalines

A series of new aryloxymethylquinoxalines, benzo[b]- and naphtho[2,1-b]furylquinoxalines, possessing potential biological activity, was prepared, characterized by IR and NMR spectroscopy and their electron ionization (EI) mass spectra studied in detail. The aryloxymethylquinoxalines were obtained by reacting halogenomethylquinoxalines with bifunctional O-nucleophiles. The benzo[b]furylquinoxalines and naphtho[2,1-b] furylquinoxalines were prepared via two routes, which differed in the order of the two cyclization steps involved in the syntheses. The composition of the ions obtained by EI mass spectrometry were determined by accurate mass measurements and the fragmentation pathways clarified by B/E linked scans and collision induced dissociation. The mass spectrometric behaviour of the compounds studied as to the possible loss of OH· radicals proved to be very characteristic.

Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds

Compounds of the formula: STR1 wherein R1 is (1) hydrogen, (2) C1 to C4 alkyl, (3) C2 to C4 alkenyl, or (4) NR2 R3, wherein R2 and R3 are independently selected from (1) hydrogen, (2) C1 to C4 alkyl and (3) hydroxyl, but R2 and R3 are not simultaneously hydroxyl; wherein X is oxygen, sulfur, SO2, or NR4, wherein R4 is (1) hydrogen, (2) C1 to C6 alkyl, (3) C1 to C6 alkoyl, (4) aroyl, or (5) alkylsulfonyl; A is selected from C1 to C6 alkylene and C2 to C6 alkenylene; n is 1-5; Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C1 to C12 alkyl, (7) C2 to C12 alkenyl, (8) C1 to C12 alkoxy, (9) C3 to C8 cycloalkyl, (10) C1 -C8 thioalkyl, (11) aryl, (12) aryloxy, (13) aroyl, (14) C1 to C12 arylalkyl, (15) C2 to C12 arylalkenyl, (16) C1 to C12 arylalkoxy, (17) C1 to C12 arylthioalkoxy, and substituted derivatives of (18) aryl, (19) aryloxy, (20) aroyl, (21) C1 to C12 arylalkyl, (22) C2 to C12 arylalkenyl, (23) C1 to C12 arylalkoxy, or (24) C1 to C12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C1 to C12 alkyl, alkoxy, and halosubstituted alkyl; Z is oxygen or sulfur; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C1 to C12 alkoyl, are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method for inhibiting lipoxygenase activity.